[1] Beers M and Berkow R.  The Merck Manual 17^th Ed. 1999.  PP: 1790-1791.

[2] Fitzpatrick T et al.  Color Atlas and Synopsis of Clinical Dermatology.  3^rd Ed.  1997.  McGraw-Hill New York.  PP364-368.

[3] Beers M and Berkow R.  The Merck Manual 17^th Ed. 1999.  PP: 1790-1791.

[4] Rembold CM and Ayers CR. Oral l-arginine can reverse digital necrosis in raynaud's phenomenon. Mol Cell Biochem. 2003 Feb; 244(1-2): 139-141.

[5] Sunderland GT, Belch JJ, Sturrock RD, Forbes CD, and McKay AJ. A double blind randomized placebo-controlled trial of hexopal in primary raynaud's disease. Clin Rheumatol. 1988 Mar; 7(1): 46-49.

[6] Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, and Jayson MI. Micronutrient anti-oxidant status in patients with primary raynaud's phenomenon and systemic sclerosis. J Rheumatol. 1994 Aug; 21(8): 1477-1483.

[7] Kremer JM and Shah DM. Fish oil dietary supplementation in patients with raynaud's phenomenon: a double blind controlled prospective study. Am J Med. 1989 Feb; 86(2): 158-164.

[8] Belch JJ et al. Evening primrose oil (Efamol) in the treatment of raynaud's phenomenon: a double blind study. Thromb Haemost. 1985 Aug; 30(54): 490-494.

[9] al-Awami M et al. Homocysteine levels in patients with raynaud's phenomenon. Vasa. 2002 May; 31(2): 87-90.

[10] Levy Y et al. Elevated homocysteine levels in patients with raynaud's syndrome. J Rheumatol. 1999 Nov; 26(11): 2383-2385.

[11] Muir AH, Robb R, McLaren M, Daly F, and Belch JJ. The use of ginkgo biloba in raynaud's disease: a double blind placebo controlled trial. Vasc Med. 2002; 7(4): 265-267.